Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells

Ruczyński, Jarosław; Wierzbicki, Piotr M.; Kogut-Wierzbicka, Marzena; Mucha, Piotr; Siedlecka-Kroplewska, Kamila; Rekowski, Piotr

doi:10.5603/fhc.a2014.0034

Cited by 37 publications

(39 citation statements)

References 104 publications

(124 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CPPs are the promising factors which can improve the introduction of bioactive substances into tumor cells [18]. To date, the CPPs-mediated cargo delivery in in vitro conditions has been widely studied [9]; however, just few studies were performed on CRC-derived cell lines. E.g.…”

Section: Discussionmentioning

confidence: 99%

“…TP reveals some characteristic features of both galanin and mastoparan since it inhibits the binding of galanin to GALR-1 receptor as well as modulates the activity of Gs proteins due www.fhc.viamedica.pl to the inhibition of GTPase activity [9]. The shorter analogs of TP (TP7-15) showed lower cytotoxity in comparison to TP, galanin and mastoparan [8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines

Wierzbicki

Kogut-Wierzbicka

Ruczyński

et al. 2015

Folia Histochem Cytobiol.

Self Cite

View full text Add to dashboard Cite

Introduction. Cell penetrating peptides (CPPs) have the ability to translocate through cell membranes with high efficiency and therefore can introduce biological agents with pharmaceutical properties into the cell. Transportan (TP) and its shorter analog transportan 10 (TP10) are among the best studied CPPs, however, their effects on viability of and cargo introduction into colorectal cancer (CRC) cells have yet not been investigated. The aim of our study was to evaluate the cytotoxic effects of TP and TP10 on representative CRC lines and the efficiency of protein (streptavidin) and siRNA cargo delivery by TP-biotinylated derivatives (TP-biot). Material and methods. HT29 (early stage CRC model) and HCT116 (metastatic CRC model) cell lines were incubated with TP, TP10, TP-biot1, TP-biot13 and TP10-biot1. The effects of studied CPPs on cell viability and cell cycle were assessed by MTT and annexin V assays. The uptake of streptavidin-FITC complex into cells was determined by flow cytometry and fluorescence microscopy, with the inhibition of cellular vesicle trafficking by brefeldin A. The efficiency of siRNA for SASH1 gene delivery was measured by quantitative PCR (qPCR). Results. Since up to 10 µM concentrations of each CPP showed no significant cytotoxic effect, the concentrations of 0.5-5 µM were used for further analyses. Within this concentration range none of the studied CPPs affected cell viability and cell cycle. The efficient and endocytosis-independent introduction of streptavidin-FITC complex into cells was observed for TP10-biot1 and TP-biot1 with the cytoplasmic location of the fluorescent cargo; decreased SASH1 mRNA level was noticed with the use of siRNA and analyzed CPPs. Conclusions. We conclude that TP, TP10 and their biotinylated derivatives can be used as efficient delivery vehicles of small and large cargoes into CRC cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines

Wierzbicki

Kogut-Wierzbicka

Ruczyński

et al. 2015

Folia Histochem Cytobiol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…[57] Up to 30 amino acid residues can comprise one CPP, of which many are arginine or lysine. [58] Although research is still being conducted concerning how CPPs enter cells to deliver their cargo, two major cellular uptake mechanisms are known: energy independent pathways and endocytosis. Examples of models that have been suggested for the latter include the inverted micelle, pore formation, carpet, and membrane thinning models.…”

Section: Cell-penetrating Peptidesmentioning

confidence: 99%

An Overview of Various Carriers for siRNA Delivery

Marquez¹,

Madu²,

Lü³

2018

Oncomedicine

View full text Add to dashboard Cite

RNA interference through the use of short interfering molecules known as short interfering RNA (siRNA) has the potential to greatly advance research in treatments for many diseases because it has the ability to silence the expression of specific genes by helping degrade target mRNA. However, challenges to siRNA delivery have made the development of safe and effective delivery systems paramount in siRNA research. Various types of delivery systems have been proposed and investigated for siRNA delivery and therapy. Although viral vectors have been established to be the most effective in delivering siRNA molecules, they also raise many concerns over biosafety, especially concerning immunogenicity. Therefore, many researchers have begun to investigate and study non-viral vectors. Non-viral vectors are studied because they are typically considered to be safer than viral vectors albeit less efficient as well. The three general non-viral vectors that have been studied for siRNA delivery are lipid-based, non-lipid organic-based, and non-lipid inorganic-based carriers. Within those general parameters of non-viral vector classification are subtypes that are each unique with their own characteristic benefits and downsides. Many of these carriers, as well as even naked siRNA, do have the potential to be modified so that siRNA delivery could be further enhanced with benefits such as greater stability and duration. Researchers still must be wary with alterations as to not interfere with siRNA function. Currently, widespread siRNA therapeutics are still out of reach, but as more advancements in siRNA research including research on their delivery mechanisms are established, the goal of integrating siRNA therapy into the treatment of a multitude of diseases becomes increasingly more of a possibility. Researchers are currently investigating how siRNA can be used to not just treat cancer but ocular and neurodegenerative diseases as well as many others. There are still many obstacles to face and overcome before siRNA therapy can be implemented into the treatment of many diseases, and more research must still be conducted concerning siRNA delivery systems. Many advancements pertaining to siRNA carriers have been made, and many more are likely on their way.

show abstract

“…Recombinant proteins are usually considered as extracellular antigens; however cell penetrating peptides and their cargos can traverse the cytoplasm membrane [10,11] and can be considered as intra cellular antigens. Recently, we reported an expression system for are combinant PTD-J-cargo protein comprising a protein transduction domain (PTD), a J domain of Hsp40, and a cargo polypeptide [12].…”

Section: Ptd-j-x Recombinant Protein Behaves As Both Intracellular Anmentioning

confidence: 99%

PTD-J domain acts as an antigen carrier for cell mediated immunity

Lin¹,

Su²,

Chuang³

2015

J Immunother Appl

View full text Add to dashboard Cite

BALB/c mice elicited specific cell-mediated immunity after transplantation with CT26 cells stably expressing human telomerase reverse transcriptase (CT26(hTERT#10)). Restingmemory T cells were reactivated in vitro by CT26(hTERT#10) cells and PTD-J-hTERTepi recombinant proteins, in which the polypeptide hTERTepi comprised TH and TC epitopes, as indicated by interferon γ (IFNγ) secretion. Preand post-injections of PTD-J-hTERTepi with in vitro expanded and differentiated dendritic cells reduced CT26(hTERT#10) tumor size. Moreover, Hsp72 activated numerous splenocytes to perform IFNγ secretion and further reduced tumor sizes.

show abstract

Cell-penetrating peptides as a promising tool for delivery of various molecules into the cells

Cited by 37 publications

References 104 publications

Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines

Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines

An Overview of Various Carriers for siRNA Delivery

PTD-J domain acts as an antigen carrier for cell mediated immunity

Contact Info

Product

Resources

About